Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.

ABSTRACT:

Background

¹⁸F-Fluorodeoxyglucose (FDG) and ¹⁸F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) positive metastatic breast cancer (MBC), but little is known about its utility in patients with breast tumors that overexpress human epidermal growth factor 2 (HER2). We hypothesize that comparing patterns of FDG and FES uptake in patients with HER2-positive versus HER2-negative MBC can guide further biologic and clinical studies into the HR/HER2-positive phenotype.

Methods

We conducted a retrospective study examining uptake in matched lesions for FES and FDG-PET scans, assessing th

SUBMITTER: Hunter NB 

PROVIDER: S-EPMC11834562 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature